Related Experiment Video
Updated: Apr 8, 2026
A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Association between the Use of Calcimimetics and Vitamin D Receptor Activators and Fracture Risk in Patients
Chikao Onogi1, Yutaka Sugiyama1,2, Yu Watanabe1,3
1Department of Nephrology, Nagoya University, Graduate School of Medicine, Nagoya, Japan.
Introduction:
Secondary hyperparathyroidism is a major complication of maintenance hemodialysis (MHD). Elevated serum parathyroid hormone levels increase fracture risk. We aimed to investigate the association between secondary hyperparathyroidism medication and fracture risk in patients undergoing MHD.
Methods:
Patient data from a large medical claims database were used. Patients receiving MHD were divided into untreated, vitamin D receptor activator (VDRA), and calcimimetic groups. The outcome was the first hospitalization due to any fracture. First hospitalization for hip or vertebral fracture was evaluated. Hazard ratios (HRs) were assessed using a weighted Cox proportional hazards model with overlap weights.
Results:
A total of 13,238, 4,847, and 5,977 patients comprised the untreated, VDRA, and calcimimetic groups, respectively. The untreated and calcimimetic groups showed a slightly lower incidence risk of any fracture than the VDRA group, although no significant difference was observed (HR, 0.85; 95% confidence interval [CI], 0.66-1.10 and HR, 0.84; 95% CI, 0.64-1.09, for the untreated and calcimimetic groups, respectively). Regarding hip fracture, the calcimimetic group exhibited a similar downward trend compared with any fracture, whereas the untreated group showed an incidence risk comparable with that of the VDRA group (HR, 0.91; 95% CI, 0.62-1.33 and HR, 0.77; 95% CI, 0.50-1.18, for the untreated and calcimimetic groups, respectively). The risk of vertebral fracture showed a downward trend in both groups, with the calcimimetic group exhibiting a significantly lower risk (HR, 0.63; 95% CI, 0.36-1.10 and HR, 0.45; 95% CI, 0.23-0.86, for the untreated and calcimimetic groups, respectively).
Conclusion:
Calcimimetic use may reduce fracture incidence in patients undergoing MHD more effectively than VDRA.
More Related Videos
08:43Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
06:47Isolation of Mesenchymal Stem Cells from Human Alveolar Periosteum and Effects of Vitamin D on Osteogenic Activity of Periosteum-derived Cells
Published on: May 4, 2018
Related Concept Videos
01:25Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
01:21Skeleton and Calcium Homeostasis
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
00:51Synthesis and Functions of Calcitonin
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
01:31Osteoclasts in Bone Remodeling
01:27Urinary Tract Calculi IV: Nutrition Therapy and Prevention